Compare FRAF & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRAF | VYGR |
|---|---|---|
| Founded | 1906 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.9M | 227.2M |
| IPO Year | 1995 | 2015 |
| Metric | FRAF | VYGR |
|---|---|---|
| Price | $59.12 | $3.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 19.9K | ★ 540.7K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | ★ 88.84 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | $14.44 | $34.04 |
| Revenue Next Year | $6.95 | $7.92 |
| P/E Ratio | $39.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.44 | $2.83 |
| 52 Week High | $60.00 | $5.55 |
| Indicator | FRAF | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 59.17 | 49.07 |
| Support Level | $54.63 | $3.71 |
| Resistance Level | $60.00 | $3.90 |
| Average True Range (ATR) | 1.72 | 0.23 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 87.77 | 44.09 |
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.